Cumberland Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc. a specialty pharmaceutical company focuses on the acquisition development and commercialization of prescription products for hospital acute care gastroenterology and oncology in the United States and internationally. The company offers Acetadote an injection for the treatment of acetaminophen poisoning; Caldolor an injection for the treatment of pain and fever; Kristalose a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ an injection for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid juvenile idiopathic and severe psoriatic arthritis as well as disabling psoriasis. In addition the company is developing ifetroban a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease systemic sclerosis and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville Tennessee.